Tag: HIV
-
Call for Talents: Transform the Fight against HIV with ADP-MENA (Activists Development Program in MENA Region)
Context: The Middle East and North Africa (MENA) region continues to face major public health challenges related to HIV/AIDS. Key populations, including young people, men who have sex with men, sex workers, and injecting drug users, face significant barriers to accessing prevention and treatment services. These obstacles are exacerbated by stigma, discrimination, and a lack…
-
TERMS OF REFERENCE FOR AUDIOVISUAL AGENCY FOR GLOBAL SUMMIT 2025
ABOUT ITPC-MENA ITPC-MENA is a regional non-governmental organization operating in the MiddleEast and North Africa region bringing together a network of community activistsunited by our vision of a longer, healthier, more productive life for people living withHIV and/or HCV. ITPC-MENA’s mission is to enable communities in need, to accessHIV, HCV and TB treatment. ITPC-MENA was formed…
-
Call for Applications for the ADP (Activist Development Program) on HIV and Leadership Training in MENA Region
*Focus only on (Egypt, Lebanon, Morocco, Jordan, and Tunisia). ITPC-MENA is delighted to announce the launch of our HIV and Leadership training program designed for young activists. This program is crafted to enhance the capacities of young activists to become leaders in the fight against HIV and AIDS. HIV is a disease that affects millions…
-
ViiV HEALTHCARE TO TRIPLE ANNUAL SUPPLY OF LONG-ACTING HIV PREP FOR LOW- AND MIDDLE-INCOME COUNTRIES: A REAL RACE IS STARTING AMONG PHARMACEUTICAL COMPANIES FOR MARKET SHARE AND PROFIT
Source : ITPC EECA Against the backdrop of a recent press release from Gilead announcing the signing of a voluntary license for the new drug lenacapavir, ViiV Healthcare has announced an increase in the supply of its injectable drug cabotegravir. This sequence of events inevitably raises the thought that a real race is starting among…
-
“Not in Our Name” – African HIV Treatment Advocates React to Gilead’s Voluntary Licensing Agreement on Lenacapavir
Press Statement – 4 October 2024 Today’s announcement by Gilead that six generic manufacturers have been awarded voluntary licenses for the production of lenacapavir—a groundbreaking, twice-yearly injectable for HIV prevention and potential treatment—raises significant concerns despite the inclusion of most African countries in the license territory. Exclusionary Practices: While most countries of the continent are part of…
-
Why the World Can’t Trust Pharmaceutical Companies to Ensure Global Access to Essential Medicines
Source : ITPC Global ITPC Global’s reaction to Gilead’s voluntary licence on lenacapravir: Gilead’s announcement of their voluntary license for lenacapavir—a groundbreaking, long-acting HIV prevention method—highlights why we cannot rely on pharmaceutical companies to deliver genuine global access strategies for the medicines, vaccines and diagnostics that the world needs. Lenacapavir (LEN), a twice-yearly injection, has…
-
ITPC-MENA Releases New Study: ‘Data Exclusivity under Moroccan Law’ – Implications for Access to Medicines
ITPC-MENA is pleased to announce the publication of its latest study, titled “Data Exclusivity under Moroccan Law: Implications for Access to Generic Medicines.” This comprehensive report examines the impact of Morocco’s data exclusivity provisions, introduced as part of the US-Morocco Free Trade Agreement (FTA), on the accessibility of affordable generic medicines. The study provides a detailed…
-
Call for Applications: Scholarships for AFRAMED 2023 Conference
We are excited to announce a fantastic opportunity for our community members in the MENA region. ITPC-MENA launched a call for scholarships “available for two to three deserving candidates to participate in the prestigious AFRAMED 2023 conference, which will be held in Beirut”. About AFRAMED 2023:The AFRAMED conference is a leading event in the field,…
-
New Study: The Impact of the COVID-19 Health Crisis on Access to HIV Services in Egypt, Morocco, Mauritania, and Tunisia.
A study was carried out by the FORSS consortium which includes (ITPC-MENA, Solidarité SIDA, AGD, ATP+, Al Shehab RdR Maroc, and M-Coalition). This recently developed report analyzes the impact of the COVID-19 pandemic on HIV-related health services in the MENA region, specifically in four countries in the region, namely (Egypt, Mauritania, Morocco, and Tunisia). ).…
-
MENA H Coalition: Call for Expression of Interest (EOI) for the Provision of Principal Recipient services
A new US$ 7.5 million programme to strengthen sustainable access to HIV prevention, treatment, and care for marginalised groups in the Middle East and North Africa has been approved by the board of the Global Fund to Fight AIDS, Tuberculosis and Malaria. The International HIV/AIDS Alliance (Frontline Aid) is the actual Principal Recipient for this…